These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 22464476)

  • 21. Rapid induction of CD95 ligand and CD4+ T cell-mediated apoptosis by CD137 (4-1BB) costimulation.
    Ebata T; Mogi S; Hata Y; Fujimoto JI; Yagita H; Okumura K; Azuma M
    Eur J Immunol; 2001 May; 31(5):1410-6. PubMed ID: 11465097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
    Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
    J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
    Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
    Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
    DeBenedette MA; Shahinian A; Mak TW; Watts TH
    J Immunol; 1997 Jan; 158(2):551-9. PubMed ID: 8992967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of CD137 and CD137 ligand in colorectal cancer patients.
    Dimberg J; Hugander A; Wågsäter D
    Oncol Rep; 2006 May; 15(5):1197-200. PubMed ID: 16596186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity.
    Drenkard D; Becke FM; Langstein J; Spruss T; Kunz-Schughart LA; Tan TE; Lim YC; Schwarz H
    FASEB J; 2007 Feb; 21(2):456-63. PubMed ID: 17167064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.
    Palazón A; Teijeira A; Martínez-Forero I; Hervás-Stubbs S; Roncal C; Peñuelas I; Dubrot J; Morales-Kastresana A; Pérez-Gracia JL; Ochoa MC; Ochoa-Callejero L; Martínez A; Luque A; Dinchuk J; Rouzaut A; Jure-Kunkel M; Melero I
    Cancer Res; 2011 Feb; 71(3):801-11. PubMed ID: 21266358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD137 enhances monocyte-ICAM-1 interactions in an E-selectin-dependent manner under flow conditions.
    Quek BZ; Lim YC; Lin JH; Tan TE; Chan J; Biswas A; Schwarz H
    Mol Immunol; 2010 May; 47(9):1839-47. PubMed ID: 20347151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis.
    Asagiri M; Sato K; Usami T; Ochi S; Nishina H; Yoshida H; Morita I; Wagner EF; Mak TW; Serfling E; Takayanagi H
    J Exp Med; 2005 Nov; 202(9):1261-9. PubMed ID: 16275763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD137 ligand interacts with CD32a to trigger reverse CD137 ligand signaling.
    Zeng Q; Soe YM; Lim Y; Sobota RM; Schwarz H
    Cell Mol Immunol; 2020 Nov; 17(11):1188-1189. PubMed ID: 32076121
    [No Abstract]   [Full Text] [Related]  

  • 31. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.
    Choi BK; Bae JS; Choi EM; Kang WJ; Sakaguchi S; Vinay DS; Kwon BS
    J Leukoc Biol; 2004 May; 75(5):785-91. PubMed ID: 14694186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of 4-1BB in immune responses.
    Vinay DS; Kwon BS
    Semin Immunol; 1998 Dec; 10(6):481-9. PubMed ID: 9826581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biphasic activity of CD137 ligand-stimulated monocytes on T cell apoptosis and proliferation.
    Kwajah M M S; Mustafa N; Holme AL; Pervaiz S; Schwarz H
    J Leukoc Biol; 2011 May; 89(5):707-20. PubMed ID: 21330351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of atherosclerosis in Balb/c apolipoprotein E-deficient mice.
    Desai A; Zhao Y; Warren JS
    Cardiovasc Pathol; 2008; 17(4):233-40. PubMed ID: 18402814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
    Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
    Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unified immune modulation by 4-1BB triggering leads to diverse effects on disease progression in vivo.
    Choi BK; Kim YH; Choi JH; Kim CH; Kim KS; Sung YC; Lee YM; Moffett JR; Kwon BS
    Cytokine; 2011 Sep; 55(3):420-8. PubMed ID: 21700476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction.
    Shao Z; Schwarz H
    J Leukoc Biol; 2011 Jan; 89(1):21-9. PubMed ID: 20643812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.
    Flórido M; Borges M; Yagita H; Appelberg R
    J Leukoc Biol; 2004 Nov; 76(5):1039-46. PubMed ID: 15316035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling.
    Langstein J; Michel J; Fritsche J; Kreutz M; Andreesen R; Schwarz H
    J Immunol; 1998 Mar; 160(5):2488-94. PubMed ID: 9498794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.